Datopotamab Deruxtecan, often abbreviated as DATO, represents the significant advancement within targeted cancer treatment. This novel antibody-drug conjugate combines the monoclonal antibody specifically targeting https://lawsonfcnt964974.pointblog.net/datopotamab-deruxtecan-the-promising-antibody-drug-compound-92097694